UCB Reveals Positive Data on Vimpat Monotherapy Study
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:45PM CDT
UCB (UCBJF) announced encouraging top-line results from a phase III non-inferiority study on Vimpat monotherapy for newly diagnosed partial-onset seizures.
ADHD: 5.66 (+0.17), APRI: 1.65 (+0.03), ANAC: 115.06 (+2.13)
Catalyst Starts Congenital Myasthenic Syndromes Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:35PM CDT
Catalyst Pharmaceuticals (CPRX) initiated a pediatric study on Firdapse for congenital myasthenic syndromes in patients aged 2 years to 17 years.
BMRN: 102.69 (+1.97), CPRX: 3.18 (+0.10), APRI: 1.65 (+0.03)
Lannett (LCI) to Buy UCB's Specialty Generics Subsidiary
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 3:10PM CDT
Lannett Company (LCI) inked a deal with UCB to buy its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc.
LCI: 47.21 (+1.09), JNJ: 95.37 (+0.29), CORT: 3.74 (-0.05)
Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 3:50PM CDT
Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), NVS: 91.90 (-0.71)
Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 274.84 (-1.32), PGNX: 5.77 (+0.26), RDY: 65.69 (-0.23)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Immunomedics Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws
Business Wire - Tue Jul 28, 2:35PM CDT
Levi & Korsinsky is investigating the Board of Directors of Immunomedics Inc. ("Immunomedics" or the "Company"
IMMU: 2.17 (+0.12)
Week In Review: Livzon Leads $26 Million Funding Of Cynvenio
ChinaBio Today - at Seeking Alpha - Sun Jun 21, 4:57AM CDT
Deals and Financings Livzon Pharma (SZ: 000513 HK: 01513) of Zuhai, China, led a $25.5 million Series B funding of Cynvenio Biosystems, a Los Angeles area diagnostics company. Cynvenio is developing LiquidBiopsy, a technology that performs genomic...
JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), PFE: 33.24 (+0.15), WX: 44.15 (+0.04)
UCB to Expand Cimzia Label Based on Positive Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 1:50PM CDT
UCB S.A. (UCBJF) announced positive results from a phase III study on Cimzia for rheumatoid arthritis in DMARD-naive patients at high risk of disease progression.
VRX: 175.94 (+4.77), BIOD: 0.43 (+0.02)
Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 3:39PM CDT
Immunomedics, Inc. (IMMU) announced that the FDA has granted fast track designation to its lead antibody-drug conjugate program sacituzumab govitecan for the treatment of patients suffering from metastatic non-small cell lung cancer.
VRX: 175.94 (+4.77), IMMU: 2.17 (+0.12), PFE: 33.24 (+0.15)
Dr. Reddy's (RDY) Earnings and Revenues Rise in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 9:00AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 49 cents, up 8.9% from the year-ago quarter.
SUPN: 14.48 (+0.16), RDY: 65.69 (-0.23)
Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 2.45 (+0.08), BIIB: 269.16 (-10.72), IMMU: 2.17 (+0.12)
UCB to Sell Indian Established Brands Portfolio to Dr. Reddy's - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 1:40PM CDT
UCB S.A. (UCBJF) will sell its established brands portfolio in India, to Dr. Reddy's Laboratories Ltd. to focus on core business.
CYTK: 7.00 (+0.02), LCI: 47.21 (+1.09), RDY: 65.69 (-0.23)
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 269.16 (-10.72), ACT: 298.98 (-2.94), VRX: 175.94 (+4.77), PCYC: 261.25 (+1.70), OSIR: 16.97 (+0.31), ACOR: 29.89 (-0.22), HSP: 89.95 (-0.01), AGN: 274.84 (-1.32), MDVN: 41.26 (+2.03), ESRX: 82.72 (+0.01), SHPG: 200.90 (-1.85), ABBV: 55.64 (-0.40), SNY: 48.75 (+0.03), ARNA: 2.19 (+0.14), REGN: 503.92 (+12.71), ABT: 41.89 (+0.73), ENDP: 64.27 (+0.85), AKRX: 29.90 (+0.39), PFE: 33.24 (+0.15), INCY: 105.00 (+1.56), SLXP: 172.96 (+0.15), AMGN: 149.59 (-0.31), MYL: 42.55 (-0.12), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), ALKS: 60.82 (+0.92), MNKD: 3.05 (+0.04), OREX: 2.53 (+0.15), NVO: 54.61 (-0.12), ISIS: 43.24 (+0.86), GERN: 3.07 (+0.10), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 269.16 (-10.72), ACT: 298.98 (-2.94), VRX: 175.94 (+4.77), PCYC: 261.25 (+1.70), OSIR: 16.97 (+0.31), ACOR: 29.89 (-0.22), HSP: 89.95 (-0.01), AGN: 274.84 (-1.32), MDVN: 41.26 (+2.03), ESRX: 82.72 (+0.01), SHPG: 200.90 (-1.85), ABBV: 55.64 (-0.40), SNY: 48.75 (+0.03), ARNA: 2.19 (+0.14), REGN: 503.92 (+12.71), ABT: 41.89 (+0.73), ENDP: 64.27 (+0.85), AKRX: 29.90 (+0.39), PFE: 33.24 (+0.15), INCY: 105.00 (+1.56), SLXP: 172.96 (+0.15), AMGN: 149.59 (-0.31), MYL: 42.55 (-0.12), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), ALKS: 60.82 (+0.92), MNKD: 3.05 (+0.04), OREX: 2.53 (+0.15), NVO: 54.61 (-0.12), ISIS: 43.24 (+0.86), GERN: 3.07 (+0.10), AZN: 32.23 (-0.16), MRK: 50.95 (-0.07), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 47.21 (+1.09), SCMP: 18.19 (-1.21), BIOD: 0.43 (+0.02)
Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics
ChinaBio Today - at Seeking Alpha - Sun Feb 08, 3:46AM CST
Deals and Financings WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech (NYSE: WX ), led a $15 million Series B financing in Claritas Genomics (see story ). Claritas is a Boston-based lab that...
MRK: 50.95 (-0.07), WX: 44.15 (+0.04)
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 8.80 (-0.95), AMGN: 149.59 (-0.31), BIOD: 0.43 (+0.02)
Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 2.17 (+0.12), PFE: 33.24 (+0.15), BIOD: 0.43 (+0.02)
UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 1:10PM CST
UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization of Parkinson's disease related therapies.
LCI: 47.21 (+1.09), ENDP: 64.27 (+0.85), BIOD: 0.43 (+0.02)
UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 200.90 (-1.85), AMGN: 149.59 (-0.31), NVS: 91.90 (-0.71)